ReviewAmerican journal of cancer research2017
Steroid hormone receptors as prognostic markers in breast cancer.
Review in American journal of cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- The rs9340799 polymorphism of the estrogen receptor alpha (ESR1) gene and its association with breast cancer susceptibility.Scientific reports · 2021Pooled it
- Emerging biomarkers in breast fibroadenoma: implications for differential diagnosis, malignant transformation, and precision medicine.Molecular biology reports · 2026Review
- A tumor-targeted heptamethine cyanine dye induces suppression of progesterone receptor activity to treat hormone receptor-positive breast cancer.Theranostics · 2026Article
- Receptor tyrosine kinases and steroid hormone receptors in breast cancer:Metabolism open · 2024Review
- Basal-epithelial subpopulations underlie and predict chemotherapy resistance in triple-negative breast cancer.EMBO molecular medicine · 2024Article
- Unveiling the Role of Hormonal Imbalance in Breast Cancer Development: A Comprehensive Review.Cureus · 2023Review
- Pharmacological Treatment of Perianal Gland Tumors in Male Dogs.Animals : an open access journal from MDPI · 2023Article
- Estradiol and Estrogen-like Alternative Therapies in Use: The Importance of the Selective and Non-Classical Actions.Biomedicines · 2022Review
- CmP signaling network unveils novel biomarkers for triple negative breast cancer in African American women.Cancer biomarkers : section A of Disease markers · 2022Article
- Molecular docking analysis of estrogen receptor binding phytocomponents identified from the ethyl acetate extract ofBioinformation · 2022Article
- CAG repeat polymorphism in androgen receptor and infertility: A case-control study.International journal of reproductive biomedicine · 2021Article
- Oleuropein is a natural inhibitor of PAI-1-mediated proliferation in human ER-/PR- breast cancer cells.Breast cancer research and treatment · 2021Article
- Androgen and Estrogen Receptor Expression in Different Types of Perianal Gland Tumors in Male Dogs.Animals : an open access journal from MDPI · 2021Article
- Spatial protein heterogeneity analysis in frozen tissues to evaluate tumor heterogeneity.PloS one · 2021Article
- Estrogen Induces Selective Transcription of Caveolin1 Variants in Human Breast Cancer through Estrogen Responsive Element-Dependent Mechanisms.International journal of molecular sciences · 2020Article
- Farnesoid X receptor as marker of osteotropism of breast cancers through its role in the osteomimetism of tumor cells.BMC cancer · 2020Article
- RNA-seq analysis identified hormone-related genes associated with prognosis of triple negative breast cancer.Journal of biomedical research · 2020Article
- Androgen Receptor Expression and Its Correlation with Clinicopathological Parameters in Iranian Patients with Triple Negative Breast Cancer.Iranian journal of pathology · 2020Article
- NEDD4 expression is associated with breast cancer progression and is predictive of a poor prognosis.Breast cancer research : BCR · 2019Article
- A Predictor of Pathological Complete Response to Neoadjuvant Chemotherapy Stratifies Triple Negative Breast Cancer Patients with High Risk of Recurrence.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the existence of many promising anti-cancer therapies, not all breast cancers are equally treatable, due partly to the fact that focus has been primarily on a few select breast cancer biomarkers- notably ERα, PR and HER2. In cases like triple negative breast cancer (ERα
Indexed as
Identifiers
28861319PMC5574935W2890364961What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.